Abstract: This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA)-peptide conjugates.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA)-peptide conjugates.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.

Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.

Abstract: Combinatorial libraries comprise first oligonucleotide analogs and second oligonucleotide analogs which are coupled together to form antisense molecules capable of binding target polynucleotides and activating an RNase, and ribozymes capable of cleaving polynucleotides.

Abstract: The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, and Paget's disease.

Abstract: The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, Paget's disease, and infections.

Abstract: Methods and compositions are provided for treating cell-proliferative related disorders such as cancer. Methods of inhibiting the growth of cancer cells comprise contacting the cancer cells with a Bcl-2 antisense oligomer; contacting the cancer cells with a tyrosine kinase inhibitor; and contacting the cancer cells with a cytotoxic chemotherapeutic agent. Methods of treating cancer in a human comprise administering to the human a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. Kits containing compositions in amounts sufficient for at least one cycle of treatment comprise a triplet combination therapy of a Bcl-2 antisense oligomer, a tyrosine kinase inhibitor, and a cytotoxic chemotherapeutic agent. In selected embodiments, the tyrosine kinase inhibitor is one that targets cell surface kinase receptors, such as VEGFR (e.g., VEGFR1, VEGFR2, VEGFR3), PDGFR, KIT, and FLT-3.

Abstract: The present invention relates to a combination of a pharmaceutical composition comprising a gallium compound, especially gallium nitrate, and one or more nonchemotherapeutic anticancer agents (NCAA) including antibodies, antisense molecules, anti-telomerase agents, aptamers, biologic response modifiers, bisphosphonates, cytotoxic fusion proteins, immunomodulatory agents, immunostimulatory agents, molecular decoys, molecular inhibitors, proteasome inhibitors, protein kinase inhibitors, retinoids, transcription factors and arsenic compounds, for the treatment of neoplasic disease in a mammal in need of treatment thereof.

Abstract: Amplification primer pairs comprising an oligonucleotide anchor and primer. The anchor has a nucleic acid chemistry which is not a substrate for reverse transcriptases and DNA polymerases, and a 3′-end which is not capable of priming DNA synthesis. The primer has a nucleic acid chemistry that is a substrate for reverse transcriptases and DNA polymerases. The anchor and the primer each include regions of nucleotide complementarity which are capable of associating with each other to form a stem structure. The stem structure includes a nucleotide sequence which is complementary to a universal primer. One primer pair (reverse pair) is used for first strand synthesis, while the second primer pair (forward pair) is used for second strand synthesis. The universal primers sustain the amplification reaction and produce the majority of the final product.

Abstract: Aspects of the invention relate to novel oligonucleotides comprising universal and generic bases for use as primers and probes, as well as, methods of using said oligonucleotides for the diagnosis of disease.

Abstract: Aspects of the invention relate novel oligonucleotides comprising universal and/or generic bases, in particular juxtaposed universal and/or generic bases, which can be used to treat or prevent disease.

Abstract: Aspects of the invention relate to novel oligonucleotides comprising universal and generic bases for use as primers and probes, as well as, methods of using said oligonucleotides for the diagnosis of disease.

Abstract: Combinatorial libraries comprise first oligonucleotide analogs and second oligonucleotide analogs which are coupled together to form antisense molecules capable of binding target polynucleotides and activating an RNase, and ribozymes capable of cleaving polynucleotides.

Abstract: Antisense oligonucleotides containing one or more degenerate and/or universal bases, and one or more modified backbone linkages, and use of these oligonucleotides for cleaving target RNA molecules.

Abstract: Combinatorial libraries comprise first oligonucleotide analogs and second oligonucleotide analogs which are coupled together to form antisense molecules capable of binding target polynucleotides and activating an RNase, and ribozymes capable of cleaving polynucleotides.

Abstract: Amplification primer pairs comprising an oligonucleotide anchor and primer. The anchor has a nucleic acid chemistry which is not a substrate for reverse transcriptases and DNA polymerases, and a 3′-end which is not capable of priming DNA synthesis. The primer has a nucleic acid chemistry that is a substrate for reverse transcriptases and DNA polymerases. The anchor and the primer each include regions of nucleotide complementarity which are capable of associating with each other to form a stem structure. The stem structure includes a nucleotide sequence which is complementary to a universal primer. One primer pair (reverse pair) is used for first strand synthesis, while the second primer pair (forward pair) is used for second strand synthesis. The universal primers sustain the amplification reaction and produce the majority of the final product.